🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 109 of 173

  1. US 8551997

    Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use

    Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8551964

    Hsp90 inhibitors with modified toxicity

    Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8551448

    Rotanone analogs: method of preparation and use

    Expires Mon Oct 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8546322

    Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8546371

    Nanoparticle formulated glycolipid antigens for immunotherapy

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8546348

    Upregulation of opioid receptors for management

    Expires Mon Sep 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8540997

    Complement receptor 1 and 2 fusion proteins

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8541231

    Elimination of N-glycolylneuraminic acid from animal products for human use

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8541371

    Treatment of conditions related to cecal ligation shock

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8541203

    Activatable binding polypeptides and methods of identification and use thereof

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8535712

    Radiation sensitive liposomes

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8536133

    Selective high-affinity polydentate ligands and methods of making such

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8535656

    Amphiphilic polymer-protein conjugates and methods of use thereof

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8536132

    Lymphatic zip codes in tumors and pre-malignant lesions

    Expires Mon Sep 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8530516

    Promoting cycling of ApoE4 isoform

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8530245

    Methods and compositions related to acetylocholine receptor conjugates

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8530621

    Combined preparation of a thiazide diuretic and a loop diuretic

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8529898

    Activatable binding polypeptides and methods of identification and use thereof

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8529872

    Seeds and markers for use in imaging

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8529916

    High concentration baclofen preparations

    Expires Mon Sep 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8524678

    Method for delivering genes

    Expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8524682

    Compositions and methods for inhibiting EZH2

    Expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8519086

    Degradable thiol-ene polymers

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8518404

    Activatable binding polypeptides and methods of identification and use thereof

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8518942

    Caspase inhibitors and uses thereof

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8518390

    Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8518871

    Skin permeating and cell entering (SPACE) peptides and methods of use thereof

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8518984

    Spiro-oxindole MDM2 antagonists

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8518870

    Compositions and methods for cancer treatment using targeted carbon nanotubes

    Expires Mon Aug 22 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8512964

    Targets for treatment of hypercholesterolemia

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8513209

    Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8513302

    Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8513489

    Uses of antimicrobial genes from microbial genome

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8513197

    Ganglioside epitopes for treating Guillain-Barre syndrome

    Expires Mon Aug 15 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8507552

    Triptolide prodrugs

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8507445

    Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8507437

    Apoptosis-modulating p53 protein therapy for vascular disorders and nanoparticles containing the same

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8507195

    MiRNAs dysregulated in triple-negative breast cancer

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8506959

    Prevention and treatment of synucleinopathic and amyloidogenic disease

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8506928

    Methods and compounds for targeting tissues

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8506944

    Replenishment and enrichment of ocular surface lubrication

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8507551

    Antimicrobial therapy for bacterial infections

    Expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8501686

    Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8501920

    Nucleic acid sequences encoding peptides with utrophin spectrin-like repeats

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8501404

    Gnaq mutations in melanoma

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8501722

    Methods and compositions for treating bacterial infection

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8501905

    Synthetic cell platforms and methods of use thereof

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8501783

    Conformationally restricted urea inhibitors of soluble epoxide hydrolase

    Expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.